Cited 2 times in
Population Pharmacokinetics of Primaquine in the Korean Population
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김춘옥 | - |
dc.contributor.author | 박경수 | - |
dc.contributor.author | 염준섭 | - |
dc.contributor.author | 채동우 | - |
dc.date.accessioned | 2021-09-29T00:43:36Z | - |
dc.date.available | 2021-09-29T00:43:36Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184005 | - |
dc.description.abstract | While primaquine has long been used for malaria treatment, treatment failure is common. This study aims to develop a population pharmacokinetic model of primaquine and its metabolite, carboxyprimaquine, and examine factors influencing pharmacokinetic variability. The data was obtained from a clinical study in 24 Korean subjects randomly assigned to normal and obese groups. The participants received primaquine 15 mg daily for 4 days and blood samples were collected at day 4. Pharmacokinetic modeling was performed with NONMEM and using simulations; the influences of doses and covariates on drug exposure were examined. A minimal physiology-based pharmacokinetic model connected with a liver compartment comprehensively described the data, with CYP450 mediated clearance being positively correlated with the body weight and CYP2D6 activity score (p < 0.05). In the simulation, while the weight-normalized area under drug concentration for primaquine in the obese group decreased by 29% at the current recommended dose of 15 mg, it became similar to the normal weight group at a weight-normalized dose of 3.5 mg/kg. This study has demonstrated that the body weight and CYP2D6 activity score significantly influence the pharmacokinetics of primaquine. The developed model is expected to be used as a basis for optimal malaria treatment in Korean patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | PHARMACEUTICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Population Pharmacokinetics of Primaquine in the Korean Population | - |
dc.type | Article | - |
dc.contributor.college | Others | - |
dc.contributor.department | Dept. of Clinical Pharmacology (임상시험센터) | - |
dc.contributor.googleauthor | Woo-Yul Lee | - |
dc.contributor.googleauthor | Dong-Woo Chae | - |
dc.contributor.googleauthor | Choon-Ok Kim | - |
dc.contributor.googleauthor | Sang-Eun Lee | - |
dc.contributor.googleauthor | Yee-Gyung Kwak | - |
dc.contributor.googleauthor | Joon-Sup Yeom | - |
dc.contributor.googleauthor | Kyung-Soo Park | - |
dc.identifier.doi | 10.3390/pharmaceutics13050652 | - |
dc.contributor.localId | A04735 | - |
dc.contributor.localId | A01422 | - |
dc.contributor.localId | A02353 | - |
dc.contributor.localId | A04014 | - |
dc.relation.journalcode | J02504 | - |
dc.identifier.eissn | 1999-4923 | - |
dc.identifier.pmid | 34063671 | - |
dc.subject.keyword | CYP2D6 | - |
dc.subject.keyword | carboxy-primaquine | - |
dc.subject.keyword | malaria | - |
dc.subject.keyword | pharmacokinetics | - |
dc.subject.keyword | population pharmacokinetics | - |
dc.subject.keyword | primaquine | - |
dc.contributor.alternativeName | Kim, Choon Ok | - |
dc.contributor.affiliatedAuthor | 김춘옥 | - |
dc.contributor.affiliatedAuthor | 박경수 | - |
dc.contributor.affiliatedAuthor | 염준섭 | - |
dc.contributor.affiliatedAuthor | 채동우 | - |
dc.citation.volume | 13 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 652 | - |
dc.identifier.bibliographicCitation | PHARMACEUTICS, Vol.13(5) : 652, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.